Ackermans & van Haaren: Outstanding results in core participations result in a strong increase of AvHs net profit for 1H2024 to EUR 200 million (+17%) Dear shareholder,…
Ackermans & van Haaren leads EUR 60 million Series B Financing Round for Confo Therapeutics, a Belgian clinical-stage biopharmaceutical company Dear shareholder,…
Ackermans & van Haaren: the General Shareholders Meeting approves all proposed resolutions by a large majority Dear shareholder,…
Ackermans & van Haaren reports outstanding Q1-results at both DEME and at the private banks Delen and Van Breda, and gives confirmation of guidance: net profit of 2024 expected to be higher than last year Dear shareholder,…
Ackermans & van Haaren realised a net profit of 399.2 million euros, thanks to a record performance of its core participations Dear shareholder,…
Ackermans & van Haaren: Well on track to post a solid set of results for the full year 2023 Dear shareholder,…
Ackermans & van Haaren realised a net profit of 708.7 million euros over the year 2022 Dear shareholder,...…
Ackermans & van Haaren announces the start of a share buyback programme of 70.0 million euros Dear shareholder,...…